Special Issue "Structure and Function of Antibodies"

A special issue of Antibodies (ISSN 2073-4468).

Deadline for manuscript submissions: 17 December 2018

Special Issue Editors

Guest Editor
Prof. Dr. Roy Jefferis

Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
Website | E-Mail
Guest Editor
Prof. Dr. William R. (Bill) Strohl

BiStro Biotech Consulting, Bridgewater, USA
Website | E-Mail
Guest Editor
Prof. Dr. Koichi Kato

Department of Creative Research, Biomolecular Organization Research Group, Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences, Okazaki, Japan
Website | E-Mail
Interests: biomolecular ordering; glycobiophysics; biomolecular NMR spectroscopy

Special Issue Information

Dear Colleagues

This Special Issue aims to review the current knowledge in the field of immunotherapy with a view to providing insight that may inform the next generation of antibody therapeutics. The design and clinical application of monoclonal antibody (mAb) therapeutics requires a comprehensive understanding of the intimate relationship between structure and function. Continued reports of adverse reactions and/or loss of efficacy are evidence of the need for a deeper and more precise understanding of sequelae following immune intervention(s); however, the unique structure of a mAb may inevitably result in elicitation of anti-drug antibodies (ADA), at least in a proportion of patients. Further insights into the mechanisms of action (MoA) in vivo require the elucidation of parameters that determine the “architecture” of the immune complexes formed, e.g., epitope specificity, affinity, isotype, etc. Advances towards the generation of structurally homogeneous mAbs, e.g., glycoforms, may be realised through cell engineering to control/regulate intracellular pathways, e.g., post-translational modifications. Next Generation Sequencing (NGS) reveals individual and population polymorphisms within immune repertoires, e.g., the antibody variable region and cellular receptor genes that may be relevant to patient stratification and the pursuit of personalized medicine. The armamentarium should be extended beyond IgG to include the other antibody isotypes, e.g., IgA, IgM, and IgE.

Prof. Dr. Roy Jefferis
Prof. Dr. William R. (Bill) Strohl
Prof. Dr. Koichi Kato
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 350 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Ig genes
  • Orthogonal physico-chemical techniques
  • IgG 3-D structure
  • Antibody paratopes
  • IgG subclasses
  • Glycoforms
  • Mechanisms of action

Published Papers

This special issue is now open for submission, see below for planned papers.

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

1) Title: IMGT® and immunoinformatics insight in antibody V and C domain structure and function.

Marie-Paule Lefranc 1,2;

1 IMGT, University of Montpellier

2 CNRS

2) Title: Micro-heterogeneity of natural and recombinant IgG antibodies.

Alain Beck; Pierre Fabre

3) Title: Dynamic views of antibody structures and functions.

Koichi Kato; Nagoya City University, Nagoya, Japan

Yanaka Saeko; Institute of Molecular Sciences, Okazaki, Japan

4) Title: IgG immune complexes, IgG-Fc binding ligands and mechanisms of action.

Gestur Vidarsson; Department of Immune Heamatology, University of Amsterdam

5) Title: Physico-chemical and functional characterisation of antibody therapeutics.

Gary Gilliland, Jeffrey Luo and Mark Chiu; Janssen R&D

6) Title: IgG Charge  (SUBMITTED)

Danlin Yang; Boehringer Ingelheim Pharmaceuticals;

Tom Laue; University of New Hampshire, Durham

7) Title: Computer aided design of antibodies for developability and stability.

Christopher Roberts; University of Delaware

8) Title: Bispecific antibody-driven T-cell redirection versus chimeric antigen receptor (CAR)-T cell redirection;

William R Strohl; BiStro Biotech Consulting

9) Title: Recombinant antibody fragments.

Martin Scott; GlaxoSmithKline

10) Title: Structure, function and developability of IgA.

Jenny Woof; University of Dundee Medical School

11) Title: Structure, function and developability of IgE.

Brian Sutton and Sophia Karagiannis; King's College London

12) Title: Structure, function and developability of IgM. 

Bruce Keyt; IGM Biosciences

13) Title: Cell engineering for customized immuno-therapeutics.

Michael J. Betenbaugh, Andrew Chung and Bojiao Yin;

Department of Chemical and Biomolecular Engineering, Johns Hopkins University

14) Title: Immunogenicity of monoclonal antibodies.

Huub Schellekens; Utrecht University, The Netherlands

Back to Top